New Data Managers Session 2



Melinda Offer, RN, MSN





Learning Objectives:

Upon completion of this session, participant will be able to:

- Understand the Procedure ID and the Risk Variable Chart
- Identify resources within the National Harvest Report



Procedure ID Chart

- Isolated Coronary Artery Bypass (CAB)
- Isolated Aortic Valve Replacement (AV Replace)
- Isolated Mitral Valve Replacement (MV Replace)
- Aortic Valve Replacement + CAB (AV Replace + CAB)
- Mitral Valve Replacement + CAB (MV Replace + CAB)
- Aortic Valve Replacement + Mitral Valve Replacement (AV Replace + MV Replace)
- Isolated Mitral Valve Repair (MV Repair)
- Mitral Valve Repair + CAB (MV Repair + CAB)





STS Adult Cardiac Surgery Database V2.9 Procedure Identification Table

Note, fields in green are new in v2.9x, fields in yellow are added or changed from the v2.81 definition

		PART 1 (PROCID 1 thro	ough 4)	
Variable Short Name/Seq#	Isolated CAB (ProcID=1)	Isolated AVR (ProcID=2)	Isolated MVR** (ProcID=3)	AVR + CAB (ProcID=4)
OpCAB/2120	Yes, planned Yes, unplanned due to unsuspected disease or anatomy	No Yes, unplanned due to surgical complication Missing	No Yes, unplanned due to surgical complication Missing	Yes, planned Yes, unplanned due to unsuspected disease or anatomy
OpCAB	OpCAB in(3,5)	OpCab in (NULL, 2,4)	OpCab in (NULL, 2,4)	OpCAB in(3,5)
OpValve/2125	<not calculation="" in="" this="" used=""></not>	• Yes	• Yes	• Yes
OpValve		Opvalve eq 1	Opvalve eq 1	Opvalve eq 1
VSAV/3390	• No	Yes, planned	• No	Yes, planned
	Yes, unplanned due to surgical complication Missing	Yes, unplanned due to unsuspected disease or anatomy	Yes, unplanned due to surgical complication Missing	Yes, unplanned due to unsuspected disease or anatomy
VSAV	VSAV in (NULL, 2,4)	VSAV in (3,5)	VSAV in (NULL, 2,4)	VSAV in (3,5)
VSAVPr/3395	<not calculation="" in="" this="" used=""></not>	Replacement	<not calculation="" in="" this="" used=""></not>	Replacement
VSAVPr		VSAVPr eq 1		VSAVPr eq 1
VSMV/3495	No Yes, unplanned due to surgical complication Missing	No Yes, unplanned due to surgical complication Missing	Yes, planned Yes, unplanned due to unsuspected disease or anatomy	No Yes, unplanned due to surgical complication Missing
VSMV	VSMV in (NULL, 2,4)	VSMV in (NULL, 2,4)	VSMV in (3,5)	VSMV in (NULL, 2,4)
VSMVPr/3500	<not calculation="" in="" this="" used=""></not>	<not calculation="" in="" this="" used=""></not>	Replacement	<not calculation="" in="" this="" used=""></not>
VSMVPr			VSMVPr eq 2	
OCarCongProc1/ 6515	Missing PFO, Primary closure Anomalous origin of coronary artery from pulmonary artery repair Anomalous aortic origin of coronary artery from aorta (AAOCA) repair	Missing PFO, Primary closure	Missing PFO, Primary closure ASD repair, Primary closure ASD repair, Patch	Missing PFO, Primary closure Anomalous origin of coronary artery from pulmonary artery repair Anomalous aortic origin of coronary artery from aorta (AAOCA) repair

00 0 0	1:	1: 200	1: AHH I 10 20 20)	1:
OCarCongProc1	Ocarcongproc1 in (NULL,10,1291,1305)	Ocarcongproc1 in (NULL,10)	Ocarcongproc1 in (NULL,10,20,30)	Ocarcongproc1 in (NULL,10,1291,1305)
OCarCongProc2/	Missing	Missing	Missing	Missing
6520	 No other congenital procedures 	 No other congenital procedures 	 No other congenital procedures 	 No other congenital procedures
	PFO, Primary closure	PFO, Primary closure	PFO, Primary closure	PFO, Primary closure
	Anomalous origin of coronary		ASD repair, Primary closure	Anomalous origin of coronary
	artery from pulmonary artery		ASD repair, Patch	artery from pulmonary artery
	repair			repair
	Anomalous aortic origin of			Anomalous aortic origin of
	coronary artery from aorta			coronary artery from aorta
OCarCongProc2	Ocarcongproc2 in	Ocarcongproc2 in (NULL, 1.10)	Ocarcongproc2 in (NULL,1,10,20,30)	Ocarcongproc2 in
	(NULL,1,10,1291,1305)			(NULL, 1, 10, 1291, 1305)
OCarCongProc3/	Missing	Missing	Missing	Missing
6525	No other congenital procedures	No other congenital procedures	No other congenital procedures	No other congenital procedures
	PFO, Primary closure	PFO, Primary closure	PFO, Primary closure	PFO, Primary closure
	Anomalous origin of coronary		ASD repair, Primary closure	Anomalous origin of coronary
	artery from pulmonary artery		ASD repair, Patch	artery from pulmonary artery
	repair			repair
	Anomalous aortic origin of			Anomalous aortic origin of
	coronary artery from aorta			coronary artery from aorta
OCarCongProc3	Ocarcongproc3 in (NULL, 1, 10, 1291, 1305)	Ocarcongproc3 in (NULL,1,10)	Ocarcongproc3 in (NULL, 1, 10, 20, 30)	Ocarcongproc3 in (NULL, 1, 10, 1291, 1305)
Tricuspid	Unplanned Surgical Complications	Unplanned Surgical Complications	All tricuspid repairs are allowed.	Unplanned Surgical Complications
Procedures:	ONLY	ONLY	Tricuspid replacements and	ONLY
VSTV			valvecotomies are only allowed if the	
VSTrReplace	VSTV is one of:	VSTV is one of:	tricuspid procedure was unplanned	VSTV is one of:
VSTrValvec	• No	• No	due to surgical complications. Must satisfy at least one of (1) or (2):	• No
3640, 3650, 3653	Yes, unplanned due to surgical	 Yes, unplanned due to surgical complication 	1.	Yes, unplanned due to surgical
	omplication Missing	Missing	VSTrReplace:	complication • Missing
	• Missing	• Missing	• No	• Missing
			Missing	
			AND	
			VSTrValvec:	
			• No	
			Missing	
			2.	
			VSTV	

			 Yes, unplanned due to surgical 	
			complication"]	
Tricuspid	VSTV in (NULL, 2,4)	VSTV in (NULL, 2,4)	[VSTrReplace in (NULL, 2) and	VSTV in (NULL, 2,4)
Procedures:			VSTrValvec in (NULL,2)]	
VSTV			OR	
VSTrReplace			VSTV eq 4	
VSTrValvec				
VSPV/3685			• No	
		• Yes, unplann	ed due to surgical complication	
			Missing	
VSPV			SPV in (NULL, 2,4)	
PrevVADExp/		• Yes, n	ot during this procedure	
3825			• No	
			Missing	
PrevVADExp			ADExp in (NULL, 1,3)	
VADImpTmg/			zation but not same OR trip as CV surgical pro-	•
3845			cal procedure (same trip to the OR)- unplanned	
		Post-Operative (after)	surgical procedure during reoperation)	
****		******	Missing	
VADImpTmg			pTmg in (NULL, 1, 4, 5)	
VADImpTmg2/			zation but not same OR trip as CV surgical pro-	•
3900			cal procedure (same trip to the OR)- unplanned	
		Post-Operative (after)	surgical procedure during reoperation)	
			Missing	
VADImpTmg2			pTmg2 in (NULL, 1, 4, 5)	
VADImpTmg3/			zation but not same OR trip as CV surgical pro-	•
3955			cal procedure (same trip to the OR)- unplanned	
		 Post-Operative (after 	surgical procedure during reoperation)	
			Missing	
VADImpTmg3			pTmg3 in (NULL, 1, 4, 5)	
VExp/3875		• Yes, n	ot during this procedure	
			• No	
***			Missing	
VExp			Exp in (NULL, 3, 2)	
VExp2/3930		• Yes, n	ot during this procedure	
			• No	
			Missing	
VExp2		VE	Exp2 in (NULL, 3, 2)	

VExp3/3985		• Yes, not dur	ring this procedure								
	1		• No								
	1	• 1	Missing								
VExp3		VExp3 ir	in (NULL, 3, 2)								
OCarLVA/4075		• No									
	1	• Missing									
OCarLVA			A in (NULL, 2)								
OCarVSD/4130			• No								
!	1	• N	Missing								
OCarVSD		OCarVSI	D in (NULL, 2)								
AortProc/2125			• No								
	1	· •	e to surgical complication								
			Missing								
AortProc	4		in (NULL, 2,4)								
EndovasProc/5066	1	• No									
			Missing								
EndovasProc			roc in (NULL, 2) Not used in this calculation>	1							
OCarAFibIntraLes/ 4040	• No	• No	<not calculation="" in="" this="" used=""></not>	• No							
OCarAFibIntraLes	Missing OcarAFibIntraLes in (NULL, 2)	Missing OcarAFibIntraLes in (NULL, 2)		Missing OcarAFibIntraLes in (NULL, 2)							
OCarAFibLesLoc/ 4191	Primarily epicardial	Primarily epicardial	<not calculation="" in="" this="" used=""></not>	Primarily epicardial							
	Missing Ocean A Fith and an analysis	Missing Grade the control of the control o		Missing Occapatity and an analysis							
OCarASDS and	OCarAFibLesLoc ne 2	OCarAFibLesLoc ne 2	<not calculation="" in="" this="" used=""></not>	OCarAFibLesLoc ne 2							
OCarASDSec/ 4035	• No • Missing	• No	Not used in this calculation.	No Missing							
4033	Missing	Missing		iviissing							
OCarASDSec	OCarASDSec in (NULL, 2)	OCarASDSec in (NULL, 2)		OCarASDSec in (NULL, 2)							
OCALASDISEC	OCALASD Sec III (NOLL, 2)	OCALASDSec III (NOLL, 2)		OCALASDISEC III (NOLL, 2)							
OCarACD/	<not calculation="" in="" this="" used=""></not>	<not calculation="" in="" this="" used=""></not>	• No	<not calculation="" in="" this="" used=""></not>							
4055	Not used in this calculation.	Not used in this calculations	Missing	CIVOL USEG III tills calculation>							
	1		Permanent Pacemaker								
OCarACD			OCarACD in (NULL, 1, 2)								
OCarACDLE/		Yes, unplanned du	e to surgical complication								
4065	1		• No								
1	1	• 1	Missing								
	_										

OCarACDLE		OCarACD.	LE in (NULL, 2,4)									
OCarLasr/4110	<not calculation="" in="" this="" used=""></not>	<not calculation="" in="" this="" used=""></not>	• No	<not calculation="" in="" this="" used=""></not>								
			Missing									
OCarLasr			OCarLasr in (NULL, 2)									
OCPulThromDis/		• No										
4085		• Missing										
OCPulThromDis		OCPulThromDis in (NULL, 1)										
OCarSubaStenRes/		• No										
4090			Missing									
OCarSubaStenRes		OCarSubaSt	enRes in (NULL, 2)									
OCarSVR/4105			• No									
			Missing									
OCarSVR		OCarSV	R in (NULL, 2)									
OCarCrTx/4120			• No									
			Missing									
OCarCrTx		OCarCr'	Γx in (NULL, 2)									
OCarTrma/4125			• No									
00 T			Missing									
OCarTrma OCTumor/4115		UCar1m	na in (NULL, 2) • No									
OC1umor/4115												
OCTumor			Missing or in (NULL, 1)									
OC1umor OCarOthr/4135		OCTUM	• No									
OCarOm/4133		_	Missing									
OCarOthr			hr in (NULL, 2)									
VSTCV/3400		OCAIO!	• No									
15101/5400		_	Missing									
VSTCV			V in (NULL, 2)									
VSTCVMit/3610		7010	• No									
		•	Missing									
VSTCVMit			Mit in (NULL, 2)									
VSTCVTri/3652			• No									
		•	Missing									
VSTCVTri			Fri in (NULL, 2)									
VSTCVPu/3695			• No									
		•	Missing									
VSTCVPu			Pu in (NULL, 2)									

CCancCase/2050	• No
CCanccase/2030	
	• Missing
CCancCase	CCancCase in (NULL, 2)
ONCCarEn/6530	• No
	 Yes, unplanned due to surgical complication
	• Missing
ONCCarEn	ONCCarEn in (NULL, 2, 4)
ONCOVasc/6535	• No
	 Yes, unplanned due to surgical complication
	• Missing
ONCOVasc	ONCOVasc in (NULL, 2, 4)
ONCOThor/6540	• No
	 Yes, unplanned due to surgical complication
	• Missing
ONCOThor	ONCOThor in (NULL, 2, 4)
ONCOther/6545	• No
	 Yes, unplanned due to surgical complication
	• Missing
ONCOther	ONCOther in (NULL, 2, 4)

OCarVSD/4130	No Missing
OCarVSD	OCarVSD in (NULL, 2)

OCarVSD/4130

Short Name for Other Cardiac VSD SEQ Number 4130 On PROC ID Chart

No – this means if you code No to this field then the procedure will stay isolated

Missing- this means if you leave this field missing then the procedure will stay isolated

Ignore the Gray Line

https://youtu.be/2-vH1cCiCts



PROC ID Scenario

Patient has CABG with A-fib Pulmonary Vein Isolation performed SEQ 4191. Will this procedure be classified as an isolated CABG?

- A. Yes
- B. No



PROC ID Scenario

Patient has CABG with A-fib Pulmonary Vein Isolation performed SEQ 4191. Will this procedure be classified as an isolated CABG?

- A. Yes Correct Answer since the PVI is a coded as a primarily epicardial procedure.
- B. No



PROC ID Scenario

If a Mitral Valve Replacement (MVR) is done with a Tricuspid Valve Repair SEQ 3646 will this procedure be classified as an isolated MVR?

- A. Yes
- B. No



PROC ID Scenario

If a Mitral Valve Replacement (MVR) is done with a Tricuspid Valve Repair SEQ 3646 will this procedure be classified as an isolated MVR?

- A. Yes Correct answer. Procedure ID algorithms for all Mitral Valve Procedures now also include intracardiac lesions and tricuspid repairs. Since it is common practice to do a full Maze procedure and/or an occasional tricuspid repair STS Leadership wanted to keep these cases in the Isolated MV Risk Algorithms.
- B. No



PROC ID Scenario

Patient has CABG performed. During the procedure, the right ventricle is lacerated. A repair of the RV laceration is performed. I have coded this as a CABG with an unplanned Other Cardiac procedure SEQ 4135 due to surgical complication. Why is this case being classified as an "Other Procedure" since the RV repair was due to surgical complication?

- A. The classification must be incorrect because all unplanned surgical complications will keep the patient in the isolated category.
- B. For this field 4135 it doesn't matter if it was for surgical complication or not. If Other Cardiac SEQ 4135 is marked as no or missing it will stay in the isolated category.



PROC ID Scenario

Patient has CABG performed. During the procedure, the right ventricle is lacerated. A repair of the RV laceration is performed. I have coded this as a CABG with an unplanned Other Cardiac procedure SEQ 4135 due to surgical complication. Why is this case being classified as an "Other Procedure" since the RV repair was due to surgical complication?

- A. The classification must be incorrect because all unplanned surgical complications will keep the patient in the isolated category.
- 3. Correct Answer For this field 4135 it doesn't matter if it was for surgical complication or not. If Other Cardiac SEQ 4135 is marked as no or missing it will stay in the isolated category.



Additional Resources Risk Model Variable Chart

It is important to understand how missing data values are handled when the STS risk-adjustment models are applied to patients with incomplete data. With the exception of age, missing data values are imputed by assigning a likely substitute value. The algorithm used for missing data imputation is described below:

Required variable: Age is the only required variable for all models. If it is missing, no value for predicted risk will be calculated.

Categorical variables: Missing data are generally assumed to have the lowest risk category. For example, if diabetes was not coded, it would be assumed to be "No"; if procedure priority were not coded, the procedure would be assumed to be "Elective." In most cases, the lowest risk category is also the most frequent. If gender is missing, Male gender (the most frequent) is imputed.

20 - OV General

Ejection Fraction (EF)

If EF is missing or <10%:

CABG Model

If HeartFailTmg is Chronic or missing and gender is Male, set EF = 55%

If HeartFailTmg is Chronic or missing and gender is Female, set EF = 58%

If HeartFailTmg is Acute or Both and gender is Male, set EF = 40%

If HeartFailTmg is Acute or Both and gender is Female, set EF = 45%

Complete Chart found in STS Harvest Report – page 20-23

The purpose of risk adjustment is to allow STS database participants to compare their performance with other participants (e.g. overall STS, like participants, region or state). By accounting for and controlling patient risk factors that are present prior to surgery, risk adjustment "levels the playing field" as best as possible.



CABG	Operative Mortality	Stroke	Renal Failure	Prolonged Ventilation	Deep Stern Inf□	Reop	Mortality/ Morbidity	Length of Stay>14	Length of Stay<6
B. Demographics									
Age (70)	×	Х	×	X	×	X	×	×	х
Gender (75)	х	Х	×	X	×	X	×	×	х
RaceBlack (160)	x	X	X	X	×	X	×	×	х
RaceAsian (165)		Х	х	Х	×	X	×	×	х
Ethnicity (185)		X	×	X	×	×	×	×	х
RaceNativeAm (170)			×	X	×	×	×	×	×
RacNativePacific (175)			×	X	×	X	×	×	х
C.Hospitalization									
SurgDt (310)			×	Х	×	X	×	×	×
PayorPrim (291)	х	Х	X	Х	×	Х	X	×	х
PayorSecond (293)	×	X	X	X	×	X	×	×	×
D. Risk Factors									
WeightKg (335)	х	X	X	X	×	X	×	×	х
HeightCm (330)	х	Х	×	X	×	X	X	×	х
Diabetes (360)	х	X	×	X	×	X	×	×	х
DiabCtrl (365)	х	Х	X	X	×	X	×	×	х
Hct (575)	х	Х	×	Х	×	X	X	×	х
WBC (565)	х	Х	×	X	×	X	X	×	х
Platelets (580)	x	X	X	X	×	X	×	×	х
CreatLst (585)	×	Х	X	X	×	×	×	×	×
Dialysis (375)	×	X	X	X	×	×	×	×	×
Hypertn (380)		X	×	X			×		х
InfEndTy (840)					×				

InfEndo (385)									
ChrLungD (405)	×	×	×	×	×		×	×	×
ImmSupp (490)	×		×	×	×		×	×	×
PVD (505)	×	х	×	×	×	×	×	×	×
CVD (525)	×	×	×	×			×	×	×
CVA (530)	×	×	×	×			×	×	×
CVAWhen (535)	х	×	×	×			×	×	×
CVDTIA (540)	×	×	×	×			×	×	×
CVDStenRt (550)	×	×	×	×			×	×	×
CVDStenLft (555)	×	×	×	×			×	×	×
CVDPCarSurg (560)	×	×		×					×
IVDrugAb (470)				×		×		×	×
Alcohol (480)	x	×	×	×	×	×	×	×	×
Pneumonia (465)			×	×			×	×	×
MediastRad (495)	×			×				×	×
Cancer (500)		×							
TobaccoUse (400)			×	×	×		×	×	×
FHCAD (355)		×	×	×			×	×	×
HmO2 (450)	×			×			×	×	×
SlpApn (460)		×		×			×		×
LiverDis (485)	×		×	×		×	×	×	×
UnrespStat (520)	×	×		×			×		
Syncope (515)	×			×		×	×		×
E. Previous Interventions									
PrCAB (670)	×		×	×	×	×	×	×	×
PrValve (675)			×	×	×	×	×	×	×
PrValveProc1 (695)				×		×	×	×	×


PrValveProc2 (700)				×		×	×	×	×
PrValveProc3 (705)				×	†	×	×	×	×
PrValveProc4 (710)			 	×	 	×	×	×	×
PrValveProc5 (715)		<u> </u>	 	×	+	×	×	×	×
POC (805)			×	×	×			×	×
POCInt1 (810)		×	×	×	×		×	×	×
POCInt2 (815)		×	×	×	×		×	×	×
POCInt3 (820)		×	×	×	×		×	×	×
POCInt3 (825)		×	×	×	×		×	×	×
		×	×	×	×		×	×	×
POCInt5 (830)									
POCInt6 (835)		×	×	×	×		×	×	×
POCInt7 (840)		×	×	×	×		×	×	×
росрсі (775)	×		×		†	×	×		×
pocpciwhen (780)	×		×		+	×	×		×
pocpciin (800)	×		×		+	×	×		×
PrCVInt (665)			×	×	 	×	×		
F. Preoperative Cardiac Status									
MIWhen (890)	×	×	×	×			×	×	×
HeartFailTmg (912)	×	×	×	×	×	×	×	×	×
ClassNYH (915)	×	×	×	×	×	×	×	×	×
	×	 	×	×	<u> </u>	×	×	×	×
CardSympTimeOfAdm (895)		<u> </u>							
CarShock (930)	×		×	×		×	×	×	×
ArrhythAtrFib (961)	×	×	×	×	×	×	×	×	×
ArrhythAFib (962)	×	×	×	×	×	×	×	×	×
ArrhythAFlutter (960)	×	×	×	×	×	×	×	×	×
ArrhythThird (970)	×	×	×	×	×	×	×	×	×

ArrhythSecond (965)	×			×	×	×	×	×	×
ArrhythSSS (955)	×			×	×	×	×	×	×
ArrhythVV (950)	×			×		×	×	х	×
G. Preoperative Medications									
MedInotr (1130)	×	×	×	×			×	×	х
MedADP5Days (1060)	×	×	×	×		×	×	×	×
MedADPIDis (1065)	×	×	×	×		×	×	×	×
MedSter (1143)	×	×	×	×		×	×	×	х
MedGP (1073)	×	×	×	×		×	×	×	x
Resusc (935)	×	×	×	×	×	×	×	×	х
medacei48 (1020)			×						
H. Hemodynamics and Cath									
NumDisV (1170)	×	×	×	×	×	×	×	×	×
PctStenLMain (1195)	×			×		×	×		
HDEF (1545)	×	×	×	×		×	×	×	×
PctStenPro□LAD (1215)		×						×	×
VDStenA (1600)	×					×			
VDStenM (1690)	×		×					×	
VDInsufA (1590)	×	×	×	×		×	×	×	×
VDInsufM (1680)	×		×	×		×	×		х
VDInsufT (1775)	×		×	×		×	×	×	х
VDAoPrimEt (1646)									
I. Operative									
Incidenc (1970)	×		×	×	×	×	×	×	×
Status (1975)	×	×	×	×	×	×	×	×	X

K. Valve Surgery								
VSTrRepair (3646)				×				
L. Mechanical Cardiac Assist Devices								
IABPWhen (3730)	×	×	×	×	X	×	X	Х
CathBasAssistWhen (3760)	×	Х	X		Х	X	Х	Х
ECMOWhen (3780)	×	Х	X		Х	X	Х	Х

Additional Resource - STS Harvest Report

- Reports are published following each quarterly database harvest and the report is provided to each eligible STS database participant.
- This report is an important quality improvement tool for participants, allowing them to compare their risk-adjusted performance with that of similar participants, participants in their geographic region and the entire body of STS database participants.
- NQF Measure and Composite Quality (STAR) Ratings results are based on a full 12 months of data ending each June or December for CABG and 36 months for Valves



Report Overviev	V	<u>1 - OV</u>
General		1 - OV
Risk Adj	ustment Supplement	5 7 - OV
STS Cor	mposite Quality Ratings and NQF Measures	64 - OV
Public Dissemir	nation of Quality Ratings	<u>105 - OV</u>
STS Composite	Quality Ratings	1
NQF Measures		<u>12</u>
Executive Sumr	nary	<u>17</u>
Major Procedure	es Mortality	23




Comparison of O/E Ratio and Odds Ratio

Because each of these statistics has its advantages, the STS has decided to provide both in the report.

OE Ratio: The benefit of O/E Ratios is that they are familiar to many surgeons and are simple to compute using an STS-certified software package.

OR Ratio: The main benefit of Odds Ratios obtained from hierarchical models is that they provide a more reliable estimate of performance for hospitals with a small number of patients.



Total ICU Hours

25th Percentile

75th Percentile

29.3

24.0

42.1

243

39.0

46.0

25.0

47.0

25.0 75.3 Duke Clinical Research Institute

In-Hospital Mortality





The following table illustrates the possible interpretations of the O/E Ratio.

Table 11. O/E Ratio Interpretations*

Statistic	Interpretation
O/E Ratio > 1	When the O/E Ratio is greater than 1, the participant had an observed outcome level that was greater than expected. The participant performed worse than expected.
O/E Ratio < 1	When the O/E Ratio is less than 1, the participant had an observed outcome level that was less than expected. The participant performed better than expected.
O/E Ratio = 1	When the O/E Ratio is 1, the participant had an observed outcome level equal to expected. The participant performed as expected.

Observed is your site compared to the expected which is computed using the risk models on all sites data.

The interpretations in this table can also be roughly extended to Odds Ratios - values less than 1 imply better than average performance, values of 1 imply average performance and values over 1 imply worse than average performance. Note that the Odds Ratio will generally be closer to 1.0 than the O/E Ratio. It is possible that these two measures will be discrepant, but only if they are close to 1.0.



Understanding Risk Adjustment The Simplified Version

Table 12. Risk-adjusted Rate Interpretations

Statistic	Interpretation
Risk-adjusted rate > STS event rate	When the risk-adjusted rate for a particular adverse outcome is greater than the STS average rate, then the participant had more of those outcomes than expected given their case-mix.
Risk-adjusted rate < STS event rate	When the risk-adjusted rate for a particular adverse outcome is less than the STS average rate, then the participant had less of those outcomes than expected given their case-mix.
Risk-adjusted rate = STS event rate	When the risk-adjusted rate for a particular adverse outcome is equal to the STS average rate, then the participant had the same number of those outcomes as expected given their case-mix.



STAR Rating

Column 4. Participant Rating.

The participant rating system assigns participants to rating categories designated by one, two, or three stars. The rating categories are defined as follows:

- ***
- → Participant performance is significantly higher than STS mean.

- **
- → Participant performance is not statistically different from STS mean.

- *
- → Participant performance is significantly lower than STS mean.

Data Completeness Requirement: Participants were excluded from the analysis if they had fewer than 10 isolated CABG procedures in the patient population and if they had more than 5% missing data on any of the following 5 NQF-endorsed process measures: use of IMA, preoperative beta blockade therapy, discharge beta blockade therapy; discharge anti-platelet medication; and discharge anti-lipid medication.

There are also thresholds that must be met for mortality fields.

Mortality fields: Mortality is counted as missing for a record if any of the fields below are missing. A value of unknown counts as missing.

- a. MtDCStat (Sequence# 5010, Vrsn. 2.81); DischMortStat (Sequence# 7005, Vrsn. 2.9)
- b. Mt30Stat (Sequence# 5015, Vrsn. 2.81; Sequence# 7001, Vrsn. 2.9)
- c. MtOpD (Sequence# 5025, Vrsn. 2.81; Sequence# 7124, Vrsn. 2.9)

If the percent missing is higher than 10% for year 2015 you are at risk of not receiving a star rating.

If the percent missing is higher than 5% for year 2016 you are at risk of not receiving a star rating.

If the percent missing is higher than 2% for year 2017 or after you are at risk of not receiving a star rating.





STS CABG Composite Quality Rating Rating Trend



Participant 99999 STS Period Ending 06/30/2018

Quality Domain	Participant Rating ¹ Jan 2016 - Dec 2016					
Overall	***	***	***	***		
Absence of Mortality	**	**	**	**		
Absence of Morbidity ²	***	**	**	**		
Use of IMA ²	**	**	**	**		
Medications ²	***	***	***	***		

^{14 =} Participant performance is significantly lower than the STS mean based on 99% Bayesian probability

^{** =} Participant performance is not significantly different than the STS mean based on 99% Bayesian probability

^{* * * =} Participant performance is significantly higher than the STS mean based on 99% Bayesian probability

²Please refer to Report Overview - STS Composite Quality Rating and NQF-Endorsed Measures for full details

Additional Resource -STS Harvest Report

Quality Domains and Study Endpoints: The following table summarizes the endpoints that were analyzed in order to assess performance within the four selected domains of quality.

Domain 1. Absence of Operative Mortality.

Proportion of patients (risk-adjusted) who do <u>not</u> experience operative mortality. Operative mortality is defined as death during the same hospitalization as surgery or after discharge but within 30 days of the procedure.

Domain 2. Absence of Major Morbidity.

Proportion of patients (risk-adjusted) who do <u>not</u> experience any major morbidity. Major morbidity is defined as having at least one of the following adverse outcomes: 1) reoperations for any cardiac reason (NQF definition); 2) renal failure; 3) deep sternal wound infection; 4) prolonged ventilation/intubation*; 5) cerebrovascular accident/permanent stroke.

Domain 3. Use of Internal Mammary Artery (IMA).

Proportion of first-time CABG patients who receive at least one IMA graft.

Note: Patients with prior CABG surgery or with documented contraindication for IMA use (subclavian stenosis, previous cardiac or thoracic surgery, previous mediastinal radiation, an emergent or salvage procedure or no LAD disease) are not included in the denominator.

<u>Domain 4. Use of All Evidence-based Perioperative Medications.</u>

Proportion of patients who receive all required perioperative medications. The required perioperative medications are: 1) preoperative beta blockade therapy; 2) discharge anti-platelet medication; 3) discharge beta blockade therapy; and 4) discharge anti-lipid medication. Note: the discharge medications were not required for patients who died prior to discharge.




Report Overview STS Composite Quality Ratings and NQF-endorsed Measures STS Report – Period Ending 06/30/2018

Title	Description	Numerator	Denominator	Exclusions
				Discharge aspirin (DCASA) OR discharge P2Y12 antagonist (DCP2Y12) OR Other discharge anti-platelet (DCOthAntiPlat) is marked "contraindicated"
Beta Blockade at Discharge	Percent of patients aged 18 years and older undergoing isolated CABG who were discharged on beta blockers	Number of patients undergoing isolated CABG who were discharged on beta blockers Number of isolated CABG procedures in which discharge beta blockers (DCBeta) is marked "yes"	All patients undergoing isolated CABG according to STS Procedure Identification algorithm	Cases are removed from the denominator if there was an inhospital mortality or if discharge beta blocker was contraindicated. Mortality Discharge Status (MtDCStat/DischMortStat), Mortality Date (MtDate), and Discharge Date (DischDt) indicate an in-hospital mortality; discharge beta blocker (DCBeta) marked as "contraindicated"
Anti-Lipid Treatment at Discharge	Percent of patients aged 18 years and older undergoing isolated CABG who were discharged on a statin or other lipid-lowering regimen NOTE: Beginning with data version 2.81 only statins are considered for this measure.	Number of patients undergoing isolated CABG who were discharged on a statin or other lipid-lowering regimen Number of isolated CABG procedures in which: Discharge statin medication (DCLipLowStat) is marked "yes"	All patients undergoing isolated CABG according to STS Procedure Identification algorithm	Cases are removed from the denominator if there was an inhospital mortality or if discharge anti-lipid treatment was contraindicated. Mortality Discharge Status (MtDCStat/DischMortStat), Mortality Date (MtDate), and Discharge Date (DischDt) indicate an in-hospital mortality; Discharge statin medication (DCLipLowStat) is marked as "contraindicated"

Report Overview STS Composite Quality Ratings and NQF-endorsed Measures STS Report – Period Ending 06/30/2018

V. Figure Interpretation

In addition to the statistics provided for each of the STS Composite Quality Domains and NQF-endorsed measures, a figure representing the distribution of values for the entire STS population is provided.



Minimum, maximum and 10th, 50th, 90th percentile values for the entire STS population



STS CABG Composite Quality Rating

Participant 99999 STS Period Ending 06/30/2018



Quality Domain	Participant Score (98% CI)	STS Mean Participant Score	Participant Rating ¹	Distrit	oution of Participant Sco • = STS Mean	res		
Jul 2017 - Jun 2018 Overall	97.7% (96.9 , 98.4)	96.6%	***	Min 90.1	10th 95.0	50th 96.8	Soth 98.0	Max 99.0



STS CABG Composite Quality Rating Domain Details

Participant 99999 STS Period Ending 06/30/2018



Quality Domain	Eligible Procedures	Detail	Count	Percent of Morbidity/Failure ¹
Jul 2017 - Jun 2018 Absence of Mortality	612	Mortality	7	
Jul 2017 - Jun 2018 Absence of Morbidity ²	612	Any Morbidity Reoperation only ³ Renal Failure only ⁴ Deep Sternal Infection/Mediastinitis only Prolonged Ventilation only Cerebrovascular Accident only Multiple Morbidities	5 3 26	7.1 % 8.9 % 5.4 % 46.4% 10.7% 21.4%
Jul 2017 - Jun 2018 Use of IMA ⁵	600	IMA Failures	5	
Jul 2017 - Jun 2018 Medications ⁶	612	Failed to Prescribe all eligible NQF-Endorsed Medications Only Failed to Prescribe Preoperative Beta Blockade Only Failed to Prescribe Discharge Beta Blockade ⁷ Only Failed to Prescribe Discharge Anti-Lipids ⁷ Only Failed to Prescribe Discharge Anti-Platelets ⁸ Failed to Prescribe Multiple Medications	25 13 3 4 2 3	52.0% 12.0% 16.0% 8.0 % 12.0%

^{&#}x27;Percentages represent the proportion that the specific morbidity or process non-compliance contributed to the total number of patients for whom credit was not received for these 'all/any or none' bundles. This information is intended to facilitate and focus process and quality improvement initiatives by providers.

²Includes Reoperations, Renal Failure, Deep Sternal Infection/Mediastinitis, Prolonged Ventilation, and CVA

³Includes Reoperations for Bleeding/Tamponade, Valvular Dysfunction, Graft Occlusion, and Other Cardiac Problems

⁴Excludes patients with preop Renal Failure or Last Creatinine >= 4.

Excludes patients with prior CABG surgery and contraindications for IMA. Refer to Report Overview for definitions.

^{*}Includes Preoperative Beta Blockade, Discharge Beta Blockade, Discharge Anti-Lipids, and Discharge Anti-Platelets. Excludes contraindicated / not indicated records.

⁷Excludes in-hospital mortalities

⁸ Anti-platelet use includes Aspirin, ADP Inhibitors, P2Y12 Antagonists and any other anti-platelet medications, and excludes in-hospital mortalities

Housekeeping Tips



Keep DCF and or your collection notes for at least 4 years.



Keep a log of 30-Day Mortality / 30 Day Readmission/ 30 Day DSWI & Infection in the event of an Audit.





Open Discussion

Please use the Q&A Function.

We will answer as many questions as possible.

We encourage your feedback and want to hear from you!



Resources

- STS National Database Webpage
- <u>STSTechSupport@IQVIA.com</u> (Uploader, DQR, Missing Variable, Dashboard, Password and Login)
- Phone Support: 1-833-256-7187
- STS National Database Feedback Form
- **Resource Documents**
 - Contact Information
 - Webinar Information
 - FAQ Document
 - Go-Live Checklist





Contact Information

- Carole Krohn, Sr. Clinical Manager, STS National Database
 - CKrohn@sts.org
 - 312-202-5847
- Database Operational Questions
 - STSDB@sts.org

